Magenta Therapeutics (Magenta Therapeutics) Scaled Net Operating Assets : -0.04 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Magenta Therapeutics's operating assets for the quarter that ended in Jun. 2023 was $1.05 Mil. Magenta Therapeutics's operating liabilities for the quarter that ended in Jun. 2023 was $4.03 Mil. Magenta Therapeutics's Total Assets for the quarter that ended in Mar. 2023 was $83.44 Mil. Therefore, Magenta Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was -0.04.

Magenta Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Magenta Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magenta Therapeutics Scaled Net Operating Assets Chart

Magenta Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.06

-0.03

0.13

Magenta Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.14	0.15	0.15	-0.01	-0.04

Competitive Comparison of Magenta Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Magenta Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Magenta Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's Scaled Net Operating Assets falls into.

Magenta Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Magenta Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(34.604	-	10.725)	/	189.934
=	0.13

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	146.645	-	112.041
=	34.604

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	40.687	-	26.138	-	3.824
=	10.725

Magenta Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2023 )
=	(Operating Assets (Q: Jun. 2023 )	-	Operating Liabilities (Q: Jun. 2023 ))	/	Total Assets (Q: Mar. 2023 )
=	(1.045	-	4.034)	/	83.441
=	-0.04

where

	Operating Assets		(Q: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	78.638	-	77.593
=	1.045

	Operating Liabilities		(Q: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	4.034	-	0	-	0
=	4.034

Magenta Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Magenta Therapeutics (Magenta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.magentatx.com

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.

Executives

Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr	officer: CHIEF ACCOUNTING OFFICER	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz	officer: CHIEF FINANCIAL OFFICER	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng	director	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa	officer: Chief Medical Officer	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp	director	2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia	director, officer: CEO and President	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness	officer: See Remarks	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles	director	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140